Avistone’s Met challenge
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
Oric looks over its shoulder
Tough equity markets as well as competitor developments prompt a narrowed focus.
Triple meeting 2024 – plenary focus
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
